Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences has submitted its financial results for the period ending September 30, 2025 (likely Q2 FY26 or H1 FY26) to the stock exchanges. The headline does not include specific revenue, profit, or margin figures, so detailed numbers are not available from this filing notice. Investors should refer to the full results document for revenue, PAT, EBITDA, and segment-wise performance. As a listed pharmaceutical company, this is a routine regulatory disclosure required under SEBI listing obligations.
This is a standard periodic results filing and, by itself, does not signal any positive or negative change for shareholders. The stock reaction will depend on the actual numbers versus market expectations, particularly growth in its chronic and acute therapy segments.